Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 1:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Estradiol Vaginal Cream Clear all
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections

NCT06353269
View directory record Official record
Conditions
Recurrent Urinary Tract Infection, Hypoestrogenism
Interventions
Estring Vaginal Product, Vagifem, Estrace 0.01% Vaginal Cream
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 21, 2026, 1:14 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Vaginal Creams to Reduce Vaginal Erosion in Pessary Users

NCT02316249
View directory record Official record
Conditions
Atrophy of Vagina, Vaginal Ulceration, Vaginitis
Interventions
Estradiol, placebo
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Sep 21, 2026, 1:14 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia

NCT01845649
View directory record Official record
Conditions
Vulvovaginal Atrophy
Interventions
WC3011 Estradiol Vaginal Cream, Vehicle
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
57
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 21, 2026, 1:14 AM EDT
Completed Not applicable Interventional Results available

Treatment of Prepubertal Labial Adhesions

NCT02218463
View directory record Official record
Conditions
Prepubertal Labial Adhesions
Interventions
Estradiol cream 0.01%, Cetaphil
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
3 Months to 12 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Sep 21, 2026, 1:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized, Single Center Pilot Study Comparing Hyaluronic Acid to Vaginal Estrogen for Treatment of Genitourinary Syndrome of Menopause

NCT04544475
View directory record Official record
Conditions
Genitourinary Syndrome of Menopause (GSM)
Interventions
Revaree, Estrace
Device · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Sep 21, 2026, 1:14 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis

NCT02195986
View directory record Official record
Conditions
Atrophic Vaginitis
Interventions
Estradiol Vaginal Cream, 0.01%, Estrace® 0.01% cream, Placebo Vaginal Cream
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
366 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
21
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Sep 21, 2026, 1:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products

NCT01813162
View directory record Official record
Conditions
HIV Prevention
Interventions
Tenofovir 1% gel, Vaginal product
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
San Francisco, California • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Sep 21, 2026, 1:14 AM EDT
Completed Phase 2 Interventional

Periurethral vs Intravaginal Estrogen for Prevention of Recurrent Urinary Tract Infections

NCT05472779
View directory record Official record
Conditions
Recurrent Urinary Tract Infection
Interventions
Periurethral application of estradiol cream, Intravaginal application of estradiol cream
Drug
Lead sponsor
Stephanie Wang Zuo
Other
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Cranberry Township, Pennsylvania • Erie, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 21, 2026, 1:14 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women

NCT01816139
View directory record Official record
Conditions
Vulvovaginal Atrophy
Interventions
Vehicle, WC3011 Estradiol Vaginal Cream
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
48
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 21, 2026, 1:14 AM EDT
Active, not recruiting Phase 4 Interventional

Preference of Women With Recurrent Urinary Tract Infection for Vaginal Estradiol Tablet vs Cream

NCT05723601
View directory record Official record
Conditions
Recurrent Urinary Tract Infection
Interventions
Estradiol vaginal cream, Estradiol Vaginal Tablet
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
20 Years to 80 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 21, 2026, 1:14 AM EDT
Recruiting Phase 3 Interventional

Topical Estrogen: Brief Intervention to Improve Postoperative Experience for Transgender Men Undergoing Hysterectomy

NCT06969326
View directory record Official record
Conditions
Postoperative Bleeding, Gender Dysphoria, Hysterectomy
Interventions
Use of topical estradiol, No intervention
Drug · Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 21, 2026, 1:14 AM EDT
Completed Phase 4 Interventional Results available

Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women

NCT01958073
View directory record Official record
Conditions
Recurrent Urinary Tract Infection
Interventions
Conjugated Estrogen Vaginal Cream, Estradiol Ring, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
La Jolla, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2020 · Synced Sep 21, 2026, 1:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Topical Estriol for Vaginal Health

NCT00908570
View directory record Official record
Conditions
Vaginal Health
Interventions
estriol, Placebo
Drug
Lead sponsor
Gynuity Health Projects
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Los Angeles, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 3, 2011 · Synced Sep 21, 2026, 1:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Influence of Reproductive Cycle and Menopause on HIV-1 Infection and TFV Gel Activity

NCT01810315
View directory record Official record
Conditions
HIV Prevention
Interventions
TFV 1% gel, Estradiol vaginal cream
Drug
Lead sponsor
CONRAD
Other
Eligibility
21 Years to 89 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Sep 21, 2026, 1:14 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Use of Topical Testosterone and Estrogen vs Estrogen Alone in Vulvodynia: a Randomized Controlled Trial

NCT07260825
View directory record Official record
Conditions
Vulvodynia, Dyspareunia, Lichen Sclerosus of Vulva
Interventions
Estradiol 0.01% Vag Cream, testosterone 0.1% and estradiol 0.01% vaginal cream
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 21, 2026, 1:14 AM EDT
Completed Not applicable Interventional

Effects of Flourish HEC on Localized Provoked Vulvodynia

NCT05478746
View directory record Official record
Conditions
Vulvodynia, Vestibulodynia, Vulvar Diseases, Vulvar Vestibulitis, Vulvar Pain
Interventions
BioNourish, a component of the Flourish HEC kit, Control - no intervention
Device · Other
Lead sponsor
Vaginal Biome Science
Other
Eligibility
18 Years to 52 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Virginia Beach, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Sep 21, 2026, 1:14 AM EDT
Completed Not applicable Interventional Results available

The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides

NCT02524769
View directory record Official record
Conditions
Overactive Bladder
Interventions
conjugated estrogen
Drug
Lead sponsor
Loyola University
Other
Eligibility
55 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Sep 21, 2026, 1:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor

NCT01778985
View directory record Official record
Conditions
Pelvic Organ Prolapse, Menopause
Interventions
Premarin, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Sep 21, 2026, 1:14 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis

NCT03294538
View directory record Official record
Conditions
Atrophic Vaginitis
Interventions
Generic Estradiol Vaginal Cream USP, 0.01%, Estrace® Vaginal Cream USP, 0.01%, Vehicle Vaginal Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
44
States / cities
Tucson, Arizona • La Mesa, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2019 · Synced Sep 21, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients

NCT00698035
View directory record Official record
Conditions
Sexual Dysfunction, Physiological
Interventions
Testosterone Cream, Estring
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Sep 21, 2026, 1:14 AM EDT
Completed Phase 3 Interventional Results available

Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy

NCT02770365
View directory record Official record
Conditions
Atrophy
Interventions
estrace cream (Perrigo), estrace cream (Reference), Placebo cream
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 21, 2026, 1:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Vaginal Estrogen on Postpartum Atrophy, Perineal Pain, and Sexual Function

NCT03493126
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Estradiol, Placebo
Drug · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Sep 21, 2026, 1:14 AM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy WC3011 (Estradiol Vaginal Cream) in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women

NCT01400776
View directory record Official record
Conditions
Postmenopausal Vulvovaginal Atrophy
Interventions
WC3011 Estradiol Vaginal Cream, Vehicle
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
70
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 21, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments

NCT03844412
View directory record Official record
Conditions
Vestibulodynia, Temporomandibular Disorder, Fibromyalgia Syndrome, Irritable Bowel Syndrome, Migraines, Tension Headache, Endometriosis, Interstitial Cystitis, Back Pain, Chronic Fatigue Syndrome
Interventions
5% lidocaine/5 mg/ml 0.02% estradiol compound cream, Nortriptyline, Placebo cream, Placebo pill
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 21, 2026, 1:14 AM EDT